Galmed Pharmaceuticals Lt... (GLMD)
Galmed Pharmaceuticals Statistics
Share Statistics
Galmed Pharmaceuticals has 2.26M shares outstanding. The number of shares has increased by -72.43% in one year.
| Shares Outstanding | 2.26M |
| Shares Change (YoY) | -72.43% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 2.22M |
| Failed to Deliver (FTD) Shares | 3.96K |
| FTD / Avg. Volume | 0.44% |
Short Selling Information
The latest short interest is 68.16K, so 3.02% of the outstanding shares have been sold short.
| Short Interest | 68.16K |
| Short % of Shares Out | 3.02% |
| Short % of Float | 3.11% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -0.11. Galmed Pharmaceuticals's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -0.11 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Galmed Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.42, with a Debt / Equity ratio of 0.
| Current Ratio | 7.42 |
| Quick Ratio | 7.42 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.3M |
| Employee Count | 3 |
| Asset Turnover | null |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -68.65% in the last 52 weeks. The beta is 0.7, so Galmed Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.7 |
| 52-Week Price Change | -68.65% |
| 50-Day Moving Average | 1.95 |
| 200-Day Moving Average | 3.28 |
| Relative Strength Index (RSI) | 40.64 |
| Average Volume (20 Days) | 894.11K |
Income Statement
| Revenue | n/a |
| Gross Profit | -31K |
| Operating Income | 7.49M |
| Net Income | -6.91M |
| EBITDA | -6.87M |
| EBIT | -6.9M |
| Earnings Per Share (EPS) | -30.05 |
Balance Sheet
The company has 4.65M in cash and 0 in debt, giving a net cash position of 4.65M.
| Cash & Cash Equivalents | 4.65M |
| Total Debt | 0 |
| Net Cash | 4.65M |
| Retained Earnings | -200.47M |
| Total Assets | 18.5M |
| Working Capital | 13.95M |
Cash Flow
In the last 12 months, operating cash flow was -5.88M and capital expenditures 0, giving a free cash flow of -5.88M.
| Operating Cash Flow | -5.88M |
| Capital Expenditures | 0 |
| Free Cash Flow | -5.88M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GLMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for GLMD.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Aug 30, 2024. It was a backward split with a ratio of 1:12.
| Last Split Date | Aug 30, 2024 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | -14.56 |
| Piotroski F-Score | 3 |